What is The Benefit of Darunavir Versus Other HIV Medications?
JUL 26, 2017 | CONTAGION® EDITORIAL STAFF
Magda Opsomer, MD, Director, Clinical Leader, Infectious Diseases and Vaccines, Janssen Pharmaceutical Companies, Belgium, explains why darunavir may be more beneficial than other HIV medications.
Interview Transcript (slightly modified for readability)
“Darunavir is a boosted protease inhibitor and what is special about it is that it has a very high genetic barrier to the development of resistance. [This] is very important when it comes to treating patients, because as we know, resistance makes it more difficult to treat patients at the end.”
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512